RecruitingPhase 4NCT06246396

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis

Sponsor

University of Florida

Enrollment

120 participants

Start Date

Jan 8, 2025

Study Type

INTERVENTIONAL

Conditions

Hypertension Resistant to Conventional Therapy

Summary

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria3

Age ≥18 years
Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
The participant agrees to have all study procedures performed

Exclusion Criteria10

Known hypersensitivity or contraindication to minocycline or other tetracyclines
Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation
Known secondary hypertension
History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year
History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year
History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
Evidence of alcoholism or drug abuse
Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
Current pregnancy or anticipated pregnancy during the study.